36902115|t|PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
36902115|a|To determine the efficacy of PT320 on L-DOPA-induced dyskinetic behaviors, and neurochemistry in a progressive Parkinson's disease (PD) MitoPark mouse model. To investigate the effects of PT320 on the manifestation of dyskinesia in L-DOPA-primed mice, a clinically translatable biweekly PT320 dose was administered starting at either 5 or 17-weeks-old mice. The early treatment group was given L-DOPA starting at 20 weeks of age and longitudinally evaluated up to 22 weeks. The late treatment group was given L-DOPA starting at 28 weeks of age and longitudinally observed up to 29 weeks. To explore dopaminergic transmission, fast scan cyclic voltammetry (FSCV) was utilized to measure presynaptic dopamine (DA) dynamics in striatal slices following drug treatments. Early administration of PT320 significantly mitigated the severity L-DOPA-induced abnormal involuntary movements; PT320 particularly improved excessive numbers of standing as well as abnormal paw movements, while it did not affect L-DOPA-induced locomotor hyperactivity. In contrast, late administration of PT320 did not attenuate any L-DOPA-induced dyskinesia measurements. Moreover, early treatment with PT320 was shown to not only increase tonic and phasic release of DA in striatal slices in L-DOPA-naive MitoPark mice, but also in L-DOPA-primed animals. Early treatment with PT320 ameliorated L-DOPA-induced dyskinesia in MitoPark mice, which may be related to the progressive level of DA denervation in PD.
36902115	0	5	PT320	Chemical	-
36902115	27	41	GLP-1 Receptor	Gene	14652
36902115	63	69	L-DOPA	Chemical	MESH:D007980
36902115	78	88	Dyskinesia	Disease	MESH:D004409
36902115	94	99	Mouse	Species	10090
36902115	109	128	Parkinson's Disease	Disease	MESH:D010300
36902115	159	164	PT320	Chemical	-
36902115	168	174	L-DOPA	Chemical	MESH:D007980
36902115	183	193	dyskinetic	Disease	MESH:D002547
36902115	241	260	Parkinson's disease	Disease	MESH:D010300
36902115	262	264	PD	Disease	MESH:D010300
36902115	266	274	MitoPark	CellLine	
36902115	275	280	mouse	Species	10090
36902115	318	323	PT320	Chemical	-
36902115	348	358	dyskinesia	Disease	MESH:D004409
36902115	362	368	L-DOPA	Chemical	MESH:D007980
36902115	376	380	mice	Species	10090
36902115	417	422	PT320	Chemical	-
36902115	482	486	mice	Species	10090
36902115	524	530	L-DOPA	Chemical	MESH:D007980
36902115	639	645	L-DOPA	Chemical	MESH:D007980
36902115	828	836	dopamine	Chemical	MESH:D004298
36902115	838	840	DA	Chemical	MESH:D004298
36902115	921	926	PT320	Chemical	-
36902115	964	970	L-DOPA	Chemical	MESH:D007980
36902115	979	1009	abnormal involuntary movements	Disease	MESH:D004409
36902115	1011	1016	PT320	Chemical	-
36902115	1080	1102	abnormal paw movements	Disease	MESH:D004409
36902115	1128	1134	L-DOPA	Chemical	MESH:D007980
36902115	1143	1166	locomotor hyperactivity	Disease	MESH:D009069
36902115	1204	1209	PT320	Chemical	-
36902115	1232	1238	L-DOPA	Chemical	MESH:D007980
36902115	1247	1257	dyskinesia	Disease	MESH:D004409
36902115	1303	1308	PT320	Chemical	-
36902115	1368	1370	DA	Chemical	MESH:D004298
36902115	1393	1399	L-DOPA	Chemical	MESH:D007980
36902115	1415	1419	mice	Species	10090
36902115	1433	1439	L-DOPA	Chemical	MESH:D007980
36902115	1477	1482	PT320	Chemical	-
36902115	1495	1501	L-DOPA	Chemical	MESH:D007980
36902115	1510	1520	dyskinesia	Disease	MESH:D004409
36902115	1524	1532	MitoPark	CellLine	
36902115	1533	1537	mice	Species	10090
36902115	1588	1590	DA	Chemical	MESH:D004298
36902115	1606	1608	PD	Disease	MESH:D010300
36902115	Positive_Correlation	MESH:D007980	MESH:D004409
36902115	Association	MESH:D004298	MESH:D010300
36902115	Positive_Correlation	MESH:D007980	MESH:D009069
36902115	Positive_Correlation	MESH:D007980	MESH:D002547

